4.8 Article

Myc Expression Drives Aberrant Lipid Metabolism in Lung Cancer

期刊

CANCER RESEARCH
卷 76, 期 16, 页码 4608-4618

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-15-3403

关键词

-

类别

资金

  1. MRC [MC_EX_G0800783, MR/P011705/1, MC_UP_A090_1006] Funding Source: UKRI
  2. Medical Research Council [MC_UP_A090_1006, MR/P011705/1, MC_EX_G0800783] Funding Source: researchfish
  3. Cancer Research UK [A12077] Funding Source: Medline
  4. Medical Research Council [MC_UP_A090_1006, MR/P011705/1] Funding Source: Medline

向作者/读者索取更多资源

MYC-mediated pathogenesis in lung cancer continues to attract interest for new therapeutic strategies. In this study, we describe a transgenic mouse model of KRAS-driven lung adenocarcinoma that affords reversible activation of MYC, used here as a tool for lipidomic profiling of MYC-dependent lung tumors formed in this model. Advanced mass spectrometric imaging and surface analysis techniques were used to characterize the spatial and temporal changes in lipid composition in lung tissue. We found that normal lung tissue was characterized predominantly by saturated phosphatidylcholines and phosphatidylglycerols, which are major lipid components of pulmonary surfactant. In contrast, tumor tissues displayed an increase in phosphatidylinositols and arachidonate-containing phospholipids that can serve as signaling precursors. Deactivating MYC resulted in a rapid and dramatic decrease in arachidonic acid and its eicosanoid metabolites. In tumors with high levels of MYC, we found an increase in cytosolic phospholipase A2 (cPLA2) activity with a preferential release of membrane-bound arachidonic acid, stimulating the lipoxygenase (LOX) and COX pathways also amplified by MYC at the level of gene expression. Deactivating MY Clowered cPLA2 activity along with COX2 and 5-LOX mRNA levels. Notably, inhibiting the COX/5-LOX pathways in vivo reduced tumor burden in a manner associated with reduced cell proliferation. Taken together, our results show how MYC drives the production of specific eicosanoids critical for lung cancer cell survival and proliferation, with possible implications for the use of COX and LOX pathway inhibitors for lung cancer therapy. (C) 2016 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据